CA3193886A1 - Systeme et procede pour generer des rapports de formule sanguine complete augmentee - Google Patents
Systeme et procede pour generer des rapports de formule sanguine complete augmenteeInfo
- Publication number
- CA3193886A1 CA3193886A1 CA3193886A CA3193886A CA3193886A1 CA 3193886 A1 CA3193886 A1 CA 3193886A1 CA 3193886 A CA3193886 A CA 3193886A CA 3193886 A CA3193886 A CA 3193886A CA 3193886 A1 CA3193886 A1 CA 3193886A1
- Authority
- CA
- Canada
- Prior art keywords
- blood
- hba1c
- cbc
- predicted
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 108
- 230000003190 augmentative effect Effects 0.000 title claims abstract description 59
- 238000004820 blood count Methods 0.000 title claims abstract description 35
- 238000012360 testing method Methods 0.000 claims abstract description 223
- 210000004369 blood Anatomy 0.000 claims abstract description 152
- 239000008280 blood Substances 0.000 claims abstract description 152
- 239000012491 analyte Substances 0.000 claims abstract description 136
- 238000010801 machine learning Methods 0.000 claims abstract description 47
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims abstract description 15
- 108091005995 glycated hemoglobin Proteins 0.000 claims abstract description 14
- 239000011710 vitamin D Substances 0.000 claims description 102
- 229940046008 vitamin d Drugs 0.000 claims description 102
- 229930003316 Vitamin D Natural products 0.000 claims description 99
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 99
- 235000019166 vitamin D Nutrition 0.000 claims description 99
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 99
- 102000001554 Hemoglobins Human genes 0.000 claims description 31
- 108010054147 Hemoglobins Proteins 0.000 claims description 31
- 238000009534 blood test Methods 0.000 claims description 30
- 210000000265 leukocyte Anatomy 0.000 claims description 28
- 238000012549 training Methods 0.000 claims description 28
- 210000003651 basophil Anatomy 0.000 claims description 19
- 238000009826 distribution Methods 0.000 claims description 19
- 210000004698 lymphocyte Anatomy 0.000 claims description 17
- 102000015779 HDL Lipoproteins Human genes 0.000 claims description 16
- 108010010234 HDL Lipoproteins Proteins 0.000 claims description 16
- 150000003626 triacylglycerols Chemical class 0.000 claims description 15
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 13
- 208000001280 Prediabetic State Diseases 0.000 claims description 13
- 210000003979 eosinophil Anatomy 0.000 claims description 13
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 12
- 238000013500 data storage Methods 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 210000003743 erythrocyte Anatomy 0.000 claims description 10
- 230000002503 metabolic effect Effects 0.000 claims description 8
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 claims description 6
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims description 6
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims description 6
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 claims description 6
- 238000005534 hematocrit Methods 0.000 claims description 6
- 210000000440 neutrophil Anatomy 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 238000007637 random forest analysis Methods 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 210000001616 monocyte Anatomy 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims description 2
- 108010082126 Alanine transaminase Proteins 0.000 claims description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 description 22
- 230000008569 process Effects 0.000 description 20
- 238000009533 lab test Methods 0.000 description 16
- 230000002159 abnormal effect Effects 0.000 description 12
- 238000004159 blood analysis Methods 0.000 description 10
- 238000010586 diagram Methods 0.000 description 9
- 102000008857 Ferritin Human genes 0.000 description 8
- 238000008416 Ferritin Methods 0.000 description 8
- 108050000784 Ferritin Proteins 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 101710085938 Matrix protein Proteins 0.000 description 2
- 101710127721 Membrane protein Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000007781 pre-processing Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000013145 classification model Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000012804 iterative process Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N20/00—Machine learning
- G06N20/20—Ensemble learning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
- A61B5/7267—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems involving training the classification device
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N5/00—Computing arrangements using knowledge-based models
- G06N5/01—Dynamic search techniques; Heuristics; Dynamic trees; Branch-and-bound
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Artificial Intelligence (AREA)
- Theoretical Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Software Systems (AREA)
- Evolutionary Computation (AREA)
- Mathematical Physics (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Data Mining & Analysis (AREA)
- General Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Molecular Biology (AREA)
- Computing Systems (AREA)
- General Engineering & Computer Science (AREA)
- Primary Health Care (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Fuzzy Systems (AREA)
- Computational Linguistics (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Signal Processing (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
L'invention concerne un procédé et un système pour générer un rapport de formule sanguine complète (FSC) augmentée, sur la base d'un test de formule sanguine complète (FSC). Le procédé comprend l'accès aux résultats du test de FSC d'un patient donné. Les résultats comprennent des valeurs mesurées pour une pluralité d'analytes sanguins; l'introduction des résultats de FSC dans une application prédictive d'analyte sanguin comprenant des modèles d'apprentissage automatique entraînés pour prédire des valeurs indicatives de numérations ou de concentrations de différents analytes sanguins cibles. Les modèles d'apprentissage automatique comprennent un classificateur d'hémoglobine glyquée (HbA1c) entraîné sur des tests de FSC d'une pluralité d'individus autres que le patient donné. Le classificateur de HbA1c délivre en sortie une valeur de HbA1c prédite indiquant une concentration de HbA1c dans le sang du patient donné, la valeur de HbA1c prédite étant basée sur les valeurs mesurées pour des analytes sanguins du test de FSC du patient donné autre que HbA1c.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063084724P | 2020-09-29 | 2020-09-29 | |
| US63/084,724 | 2020-09-29 | ||
| PCT/CA2021/051347 WO2022067426A1 (fr) | 2020-09-29 | 2021-09-28 | Système et procédé pour générer des rapports de formule sanguine complète augmentée |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3193886A1 true CA3193886A1 (fr) | 2022-04-07 |
Family
ID=80949047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3193886A Pending CA3193886A1 (fr) | 2020-09-29 | 2021-09-28 | Systeme et procede pour generer des rapports de formule sanguine complete augmentee |
Country Status (2)
| Country | Link |
|---|---|
| CA (1) | CA3193886A1 (fr) |
| WO (1) | WO2022067426A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102023108748A1 (de) * | 2023-04-05 | 2024-10-10 | RobotDreams® GmbH | Computerimplementiertes Verfahren zur Bestimmung der Zustände in vivo und in vitro durch Analyse der in einem hämatologischen Analysegerät gemessenen Blutparameter |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7027359B2 (ja) * | 2019-02-20 | 2022-03-01 | 株式会社日立製作所 | ヘルスケアデータ分析装置及びヘルスケアデータ分析方法 |
-
2021
- 2021-09-28 WO PCT/CA2021/051347 patent/WO2022067426A1/fr active Application Filing
- 2021-09-28 CA CA3193886A patent/CA3193886A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022067426A1 (fr) | 2022-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fraser et al. | Proposals for setting generally applicable quality goals solely based on biology | |
| Cabitza et al. | Machine learning in laboratory medicine: waiting for the flood? | |
| Randell et al. | Delta checks in the clinical laboratory | |
| Allen et al. | Approaches to minimising the epidemiological impact of sources of systematic and random variation that may affect biochemistry assay data in UK Biobank | |
| JP7286863B2 (ja) | 医療データの自動化された検証 | |
| Campora et al. | Determination of haematological reference intervals in healthy adult greyhounds | |
| US20080243394A1 (en) | System, method and computer program product for manipulating theranostic assays | |
| Badrick et al. | Implementation of patient-based real-time quality control | |
| US11885733B2 (en) | White blood cell population dynamics | |
| Seyahi et al. | Artificial intelligence and kidney transplantation | |
| Chaudhury et al. | White blood cell population dynamics for risk stratification of acute coronary syndrome | |
| WO2023186051A1 (fr) | Procédé et appareil de diagnostic auxiliaire, ainsi qu'appareil de construction, appareil d'analyse et produit associé | |
| Mitani et al. | Highly accurate and explainable detection of specimen mix-up using a machine learning model | |
| Westgard et al. | Design and assessment of average of normals (AON) patient data algorithms to maximize run lengths for automatic process control | |
| Lippi et al. | Continuous-flow automation and hemolysis index: a crucial combination | |
| Smith et al. | A direct comparison of patient-based real-time quality control techniques: The importance of the analyte distribution | |
| Obstfeld et al. | Data mining approaches to reference interval studies | |
| Fermo et al. | Screening tools for hereditary hemolytic anemia: new concepts and strategies | |
| Benirschke et al. | Detection of falsely elevated point-of-care potassium results due to hemolysis using predictive analytics | |
| Sung et al. | Establishment of pediatric reference intervals for routine laboratory tests in Korean population: a retrospective multicenter analysis | |
| Alfieri et al. | Continuous and early prediction of future moderate and severe Acute Kidney Injury in critically ill patients: development and multi-centric, multi-national external validation of a machine-learning model | |
| CA3193886A1 (fr) | Systeme et procede pour generer des rapports de formule sanguine complete augmentee | |
| Deng et al. | Characterizing risk of in-hospital mortality following subarachnoid hemorrhage using machine learning: a retrospective study | |
| Bracho | Reference intervals of automated reticulocyte count and immature reticulocyte fraction in a pediatric population | |
| Sadler | Using the variance function to estimate limit of blank, limit of detection and their confidence intervals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230609 |
|
| EEER | Examination request |
Effective date: 20230609 |
|
| EEER | Examination request |
Effective date: 20230609 |
|
| EEER | Examination request |
Effective date: 20230609 |